GlaxoSmithKline PLC — Director's Dealing 2020

Jun 18, 2020

National Storage Mechanism | Additional information

RNS Number : 4041Q

GlaxoSmithKline PLC

18 June 2020

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Waterhouse
b)	Position/status	CEO of ViiV Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the final vesting on 15 June 2020 of an award made on 15 June 2017 under the GlaxoSmithKline Deferred Investment Award programme, Ms Waterhouse will receive a cash payment of £75,564.47 less applicable tax withholding in respect of 4,720.419 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	16.008	4,720.419
d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2020-06-15
f)	Place of the transaction	N/A

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHFVLFFBQLLBBX